Life Sciences Archive » December, 2023

Life Sciences - December, 2023

260 articles

• Apple Watch Import Ban Put On Hold By Fed. Circ.
• White House Won't Veto ITC Apple Watch Import Ban
• Crowell & Moring Reaches Deal In Walgreens-Humana Conflict
• Investor Sues Illumina, Ex-Execs Over Unwound Grail Deal
• The Most-Read Legal Industry Law360 Guest Articles Of 2023
• Covington-Led Bristol Myers To Buy Karuna In $14B Deal
• The 5 Biggest First Circuit Rulings Of 2023
• GSK, Kaleo Scale Back Orange Book IP In FTC Campaign
• Becton Investors Seek OK Of $85M Deal Over Alaris Recall
• Alexion 'Misled' USPTO About Blood Drug Patent, PTAB Says
• HHS Seeks Early Win Defending Medicare Drug Price Program
• Judge Asked To Double $31M Genetic Testing Verdict
• FTC, DOJ End 2023 With New Guidance, Lingering Challenges
• Inside Higher Education's New FCA Liability Challenges
• J&J Consumers' Adviser Keeps Bonus Pay In Talc Unit Ch. 11
• AI Executive Order's Life Science, Healthcare Industry Effects
• 5 Most Notable Class Action Standing Cases Of 2023
• NJ Court Won't Rethink Quashing J&J's Law Firm Subpoenas
• HHS Advisory Highlights Free Product Inducement Risks
• Haynes Boone Hires Rothwell Figg Life Sciences Counsel
• Attorneys' Busiest Times Can Be Business Opportunities
• Exxon, Chevron Top 2023's 10 Largest M&A Deals
• 2024 Trends To Watch As AI And IP Litigation Intersect
• Top Connecticut Cases Of 2023
• 11 Deals That Shaped Healthcare And Life Sciences In 2023
• Beasley Allen Atty Slams J&J's 'Locker-Room Brawl' DQ Bid
• Medical Device Cos. Settle Trade Secrets Suit For $8M
• Top Product Liability Cases Of 2023
• ITC Rejects Apple's Bid To Put Apple Watch Ban On Hold
• FDA Offers Guide On Real-World Data For Device Submissions
• Biochemical Co. Amyris OK'd To Sell Celebrity Brands
• The Top Bankruptcy Cases And Issues Of 2023
• FDA Drops List Of Off-Patent Drugs Without Approved Generic
• 9th Circ. Scienter Ruling May Strengthen FDA's Leverage
• SomaLogic Founder Sues In Del. Chancery To Block $1B Deal
• No Discovery In Regeneron FCA Case Until 1st Circ. Rules
• In The World Of Legal Ethics, 10 Trends To Note From 2023
• Fed. Circ. Won't Touch Hypertension Drug Patent Ruling
• Stimwave Buyer Can Enforce Sale In 'Disturbing' Domain Row
• Choppy Conditions Tripped Up Capital Markets Again In 2023
• Pharma Co. Impel Hits Ch. 11 With $127M Debt And Sale Plans
• Cannabis Co. Urges Judge To Deny Win In IP Row
• AmerisourceBergen Ruling Sharpens Del.'s Compliance Focus
• Indicted Stimwave CEO Hit With $41M Civil Suit From SEC
• Invisalign Fights Social Media Class Notice In Antitrust Suits
• All 5 Of Plaintiffs' Expert Witnesses Barred In Tylenol MDL
• Doctor Groups Say Ark. Law Blocks Lifesaving Gender Care
• Anesthesiologists Say CMS Reimbursement Math Is Unlawful
• Swiss Hearing Implant Co. Lands $1.4M Patent Verdict In Del.
• Bradley Adds Healthcare, Real Estate Attys To Nashville Office
• The States That Legalized Pot In 2023, And One That Didn't
• Acadia Investor Says Officers Overhyped Drug's Prospects
• Philips Unit Inks $14.7M FCA Deal For Cardiac Monitoring Bills
• What China's New Rare Disease Catalog Means For Drug Cos.
• 9th Circ. Panel Reverses Man's Disability Coverage Denial
• Emcure Seeks Fees After $950M Vax Trade Secrets Suit Nixed
• How Attorneys Can Be More Efficient This Holiday Season
• Zymergen Gets Conditional OK For Ch. 11 Asset Sales
• 2nd Trader Avoids Prison In Covington Info Theft Case
• The Biggest PTAB Developments In 2023
• Steward Health Paid Boston Cardiac Doc Kickbacks, Feds Say
• Del. Justices Reverse Chancery AmerisourceBergen Suit Toss
• Olympics Track Coaches Charged In NY With Doping Athletes
• HHS Says Chambers Have No Place In Drug Price Dispute
• SC Judge Won't Reconsider Foam Co. Dismissal Ruling
• Fed. Circ. Sends Philips' Row With Fitbit Back To Lower Court
• 'Superb' Juul MDL Attys Get $76.5M, But Diversity Issue Noted
• Life Sciences Co. Sells Its Spine Biz To H.I.G. In $375M Deal
• Judge Partially Tosses Texas Suit Over Failed Gov't Contract
• Stimwave Buyer Pans Ex-CEO's 'Nonsensical' Domain Claim
• Feds Defend Chevron Deference In Second High Court Case
• Catching Up With Delaware's Chancery Court
• 3 Defense Takeaways From The Bankman-Fried Trial
• Apple To Halt Apple Watch Sales Due To Masimo Patent Case
• Children's Book Writing Makes Me A Better Lawyer
• 5th Circ. Says FTC Must Reconsider $8B Illumina-Grail Merger
• DOJ Slams Teva's Bid For Answers On Dropped Case
• IPOs In 2024 Will Be Invite-Only, Life Sciences Insiders Say
• Feds Urge 8th Circ. To Affirm Block On Ark. Trans Care Ban
• Patent Office Says Double Patenting Ruling Was 'Textbook'
• Artis Ventures Closes $200M Fund For TechBio Investments
• Autism Care Provider Gets 366-Day Term For Medicaid Fraud
• Zymergen Names 2 Successful Bidders In Ch. 11 Auction
• Amyris Says DIP Lender Will Bid For Remaining Assets
• Amendment Sinks Ohio AG's Bid To Resume Abortion Limits
• Boston Scientific Reaches $38.5M Deal To End Investor Suit
• How The PTAB Landscape Shifted In 2023
• New Pharma Guidelines Bring Pitfalls For Compounders
• MSU Reverses Stance, Agrees To Release Nassar Documents
• What Happens If High Court Rejects Releases In Purdue Ch. 11
• Exec's Parents Say Examiner Botched Autopsy, Leaked Info
• Motley Rice 'Weaponized' Gov. Info For Opioid MDL, PBM Says
• Taxation With Representation: Latham, Freshfields, Debevoise
• 1st Circ. Backs Off-Label Marketing Convictions
• Acadia Drug Patent Survives Attack In MSN Case
• IP Forecast: Del. Judge To Hear Kidney Drug Case
• Ohio Clinics Double Down On Suit Over 6-Week Abortion Ban
• Feds Seek Up To 2 Years For Merck Merger Tippee
• Judge Divvies Up Atty Fees From $785M FCA Deal
• Mass. Pharmaceutical Co. Banned From Making Drugs
• Shkreli's Lifetime Pharma Ban Goes Too Far, 2nd Circ. Told
• FDA's Recent Litigation Records Are Strong, But Imperfect
• Jury Finds No Infringement Of Spinal Implant Patents
• Coming To Terms With Means-Plus-Function Patent Claims
• FDA Seized $18M Worth Of Imported Vapes At LA Airport
• Del. Justices Spike EpicentRx Appeal For Target Co. Docs
• Fed. Circ. Backs Rejection Of Institut Pasteur's Patent App
• Harvard Doctor Secretly Impregnated Me In 1980, Patient Says
• A Look Back At The Abortion Battles Of 2023
• Military Health System Lacks Opioid Rx Controls, IG Finds
• 5 Steps For Healthcare Companies After Biden's AI Order
• Giving The Gov't Drug Patent March-In Authority Is Bad Policy
• The Biggest Patent Rulings Of 2023
• The Biggest Legal Ethics Cases Of 2023
• Split 11th Circ. Panel Backs Walgreens Defeat Of FMLA Suit
• Jazz, Express Scripts Beat Calif. Overcharge Suit, For Now
• EU OKs $22B Bioscience Cos. Merger After Remedies
• 6 Biggest Healthcare Fraud Cases Of 2023
• Verve Motion Scores $20M In Series B Round
• Morgan Lewis Guides Integra On $275M Pharma Biz Deal
• How Clients May Use AI To Monitor Attorneys
• DEA Must Consult FDA On Psilocybin Petition, 9th Circ. Told
• Supreme Court To Consider Fight Over Abortion Medication
• Sidley Hired For HeadFirst's £483M Bid For Recruiter Impellam
• Revolution Beauty Settles With Ex-Chair Over £28M Deal
• AstraZeneca Urges Chancery To Toss $3B Viela Bio Sale Suit
• Longhorn Points Finger At Ex-Counsel After PTAB Sanctions
• Whistleblower Says Allergan Knowingly Overbilled Medicaid
• 7 Enforcement Predictions For US Export Controls, Sanctions
• Novartis To Pay Daiichi $182M In Deal To End Appeal
• NYC Leader Of Black-Market HIV Drug Scheme Pleads Guilty
• Senate Health Panel OKs Bipartisan Opioid Treatment Measure
• Quinn Emanuel Escapes Drug Pricing Antitrust Subpoena
• Amyris Gets OK To Solicit Ch. 11 Plan Votes
• Paul Weiss M&A Counsel Shifts Practice To Goodwin In NY
• Freshfields-Led AstraZeneca To Buy Vaccine Maker For $1.1B
• Sanofi Scraps $755M Licensing Deal Amid FTC Challenge
• Patent Deals Don't Support $410M DNA Test Suit, Court Told
• Texas High Court Revokes Order Allowing Emergency Abortion
• Chamber Finds Drug Price Measures Will Stifle Research
• House Passes Healthcare Pricing Transparency Bill
• Healthcare-Focused SPAC Gardiner Acquisition Calls It Quits
• Eli Lilly Must Face Most Claims In Diabetes Medication Suit
• Amyris Creditors Slam 'Tainted' Ch. 11 Plan
• One Natera Patent Falls, But Others Survive
• Moderna Says Pfizer COVID Vax Patent Challenges Fail Fintiv
• Kaiser Beneficiaries Win Class Cert. In Discrimination Suit
• Conn. Seeks Default, Contempt In $10.9M Drug Kickback Case
• Novo Nordisk Says Fed Drug Pricing Unseen Even In Wartime
• Kristen Bell's Baby Co. Gets OK For $65M Ch. 11 Sale
• Biden Would Veto Rulemaking Bill Citing 'Unnecessary Delays'
• How AI Executive Order Aims To Compete For Foreign Talent
• Medtronic Says Promotions Not Basis For FCA Case
• ESG Around The World: Singapore
• Sanofi Tells 3rd Circ. Post-Ch. 11 Drug Sales Triggered Deal
• Top Court Won't Hear Hedge Fund Priest's Appeal In SEC Case
• Mich. AG Asks 6th Circ. To Deny Christian Health Clinic Appeal
• Scrubs Co. Sues Attys Over Fees In Lost False Ad Suit
• The Pop Culture Docket: Judge D'Emic On Moby Grape
• Catching Up With Delaware's Chancery Court
• Navigating Asset Tracing Challenges In Bankruptcy
• Jury Frees Abbott Labs From Sales Exec's Age Bias Suit
• Cigna Opts For $10B Buyback As Humana Deal Rumors Fizzle
• High Court Won't Review CoolSculpting Warning Suit
• Texas High Court Halts Order Granting Emergency Abortion
• Circuit-By-Circuit Guide To 2023's Most Memorable Moments
• New Drug Patent Proposal Sparks Worry Over Gov't Overstep
• Carriers Urge Pa. Justices To Flip Policyholder Pandemic Win
• JPML Moves Actions On Ineffective Decongestants To NY
• Ex-CEO Admits Securities Fraud In Fake COVID Test Case
• SC Argues With 4th Circ. Over Right To Sue Under Medicaid
• Barnes & Thornburg Adds Healthcare Atty From Krieg DeVault
• Reading The Fine Print On FDA's Prescription Drug Ad Rule
• Magistrate Pans Countersuit To Rwanda's $40M Fraud Claim
• Biomedical Cos. Score $62M Award In Trade Secrets Trial
• Novo Nordisk Must Face Bulk Of Woman's Ozempic Injury Suit
• Perils Of Incorporation By Reference At The Federal Circuit
• J&J Hit With Suit Over Stelara Exclusivity
• UK Litigation Roundup: Here's What You Missed In London
• US Glycine Co. Rips Commerce's Refusal To Expand Duties
• Performing Music Makes Me A Better Lawyer
• Generics Price-Fixing Cases Should Stay In MDL, Judge Says
• Gilead Sued In Calif. Over Remdesivir COVID-19 Claims
• 6th Circ. Judge Doubts Error In Tossing Diabetes Drug MDL
• Teva Says EpiPen Suit Only Remedy For Colo. Takings
• Fed. Circ. OKs Mixed Ruling For Lundbeck In Trintellix IP Case
• Congress Members Pitch Bill Letting States Set Pot Policy
• Feds Say Lack Of Funding, Officers Fueling Native Drug Crisis
• Pfizer Unit Agrees To Construct Floodplain At Superfund Site
• 'Patient' Definition Ruling Raises Discount Drug Questions
• Texas Judge Says Woman Can Get Abortion Despite State Ban
• Amyris Files Ch. 11 Plan With $23M Creditor Deal
• Biden Admin Looks To Take Over Expensive Drug Patents
• Wellness or Medical? Device-Maker Attys Look for Answers
• Cancer Test Co. Overpromised Insurer Coverage, Suit Says
• Cooley Atty Can't Ax 'Rather Harsh' Sanctions, 3rd Circ. Says
• Fed. Circ. Wrestles With Apple Bid To Ax More Masimo Patents
• Ex-USPTO Directors Rally Against WTO IP Waiver
• Boston Biotech Seeks $716K For COVID-19 Test Default
• Patent Suit Deal Sounds Like 'Money Laundering' To Judge
• Kirkland-Led AbbVie To Pay $8.7B For Cerevel Therapeutics
• Tech Players Square Off In $4M Fight Over Penthouse Elevator
• Apple Allowed To Seal Smartwatch Competition Hearing
• CVS Hit With Class Action Following Eye Drop Recall
• Breaking Down High Court's New Code Of Conduct
• Judge Orders 3 Case Tracks, Appoints Counsel In Insulin MDL
• Philips Settles Claim Rival's Worker Hacked Ultrasound Tech
• Ex-CEOs Must Face Claims They Pilfered Bioscience Co.'s IP
• Patent Board Says Goodnight To NYU's Sleep Machine Patents
• Texas Sued By Pregnant Woman Seeking Abortion Care
• Group Says US Gov't Must Address Drug 'Patent Thickets'
• Abbott Labs Says Sales Exec Fired Due To Attitude, Not Age
• Mintz Bolsters Healthcare Practice With Wiley Partner
• Ex-Hospital CFO, 3 Doctors Settle Kickback Case For $880K
• How Purdue High Court Case Will Shape Ch. 11 Mass Injury
• Senators Debate Reimbursement Ideas To Fix Drug Shortages
• Bristol-Myers Decries Blue Cross Unit's Last-Minute Dropout
• Court Denies Duty-Free Treatment For Specialty Baby Formulas
• PTAB To Eye Hormone Drug Again In Patent Fight
• Drug Co. Aceragen OK'd For Chancery-Overseen Liquidation
• Legal Profession Gender Parity Requires Equal Parental Leave
• PacBio Sees Most Of Its In-House Legal Dept. DQ'd In IP Row
• Tenn. Seeks To Bar HHS Title X Denial Over Abortion Stance
• Pa. Court Told Overdose Prevention Org. Has Religious Views
• Fed. Circ. Not Sure It Should Answer PREP Immunity Question
• Wash. Judge Nixes HDT's $950M mRNA Vax Trade Secrets Suit
• Dickinson Wright Adds Lewis Brisbois IP Atty In Denver
• Seagen Looks To Revive Cancer Drug Claims In Daiichi Fight
• Leave The Courtroom Doors Open, Says Apple Foe
• Justice Jackson Skeptical Of Sacklers' Ch. 11 Liability Shield
• Parents Want Abbott Docs On Calif. Law In Baby Formula MDL
• Justices Take Cautious Look At Sacklers' Purdue Immunity
• AstraZeneca Criticizes HHS For Bid To Skirt Drug Price Suit
• Pharma Heirs Owe $5.4M In Tax On Merger, Tax Court Says
• Ex-FBI Trainee Cops To Trading On Covington Insider Info
• Clinical Lab Group Slams FDA Proposal To Regulate Lab Tests
• Pear Therapeutics Seeks WARN Act Class Suit Settlement
• Kristen Bell's Baby Co. Eyes $65M Early-Bidder Ch. 11 Sale
• J&J, Ethicon Settle 224 Hernia Mesh Defect Suits In MDL
• Catching Up With Delaware's Chancery Court
• Sidley-Led Roche To Buy US Drugmaker For Up To $3.1B
• Justices Call O'Connor 'American Hero,' 'Perfect Trailblazer'
• Natera Wins Cancer Test Injunction After $19M IP Verdict
• Former Clerks Say Justice O'Connor Still Worth Emulating
• Voters Worried About Health Care Affordability, Poll Shows
• Up Next At High Court: Purdue Pharma, Taxes & Job Transfers
• La. Lab Owner Indicted For $148M Urine Test Billing Scheme
• Congress Has Chance To Adjust Hemp Policy, Report Says
• Med Tech Co. Sues AI Maker Over Use Of 'Judi' Mark
• Mass. Lab Execs Guilty Of Bloodwork Kickback Conspiracy
• Clinic Owner, Pharma Tech Sentenced For Fake Clinical Trial
• Leases Don't Disqualify Small Biz Bankruptcies, Court Rules
• Xencor Scoffs At USPTO Bid To Send Case To Review Panel
• J&J MedTech Buys Heart Device Maker Laminar In $400M Deal
• Managing ANDA Venue Issues As Del. And NJ Filings Rise
• Purdue's High Court Case Puts Bankruptcy Pragmatism On Trial
• 4 Decisions For Which Justice O'Connor Will Be Remembered
• Justice O'Connor Shattered Barriers, Built Bridges
• Sandra Day O'Connor, First Woman On Supreme Court, Dies
• Writing Thriller Novels Makes Me A Better Lawyer